SURF - Surface Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.0550
+0.0150 (+0.37%)
As of 2:11PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.0400
Open3.9800
Bid4.0100 x 900
Ask4.0700 x 800
Day's Range3.9570 - 4.0700
52 Week Range3.4490 - 18.1800
Volume34,974
Avg. Volume61,146
Market Cap112.864M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3310
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

    CAMBRIDGE, Mass., April 24, 2019 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.

  • GlobeNewswire24 days ago

    Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer

    Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Wendy Dwyer as chief business officer. Ms. Dwyer will be responsible for Surface’s business development, program and alliance management, and portfolio strategy functions.

  • GlobeNewswire2 months ago

    Surface Oncology to Present at the 39th Annual Cowen Healthcare Conference

    CAMBRIDGE, Mass., March 04, 2019 -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.

  • Could Surface Oncology, Inc.’s (NASDAQ:SURF) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Surface Oncology, Inc.’s (NASDAQ:SURF) Investor Composition Influence The Stock Price?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Surface Oncology, Inc. (NASDAQ:SURF) should be awareRead More...

  • GlobeNewswire3 months ago

    Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388

    Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting IL-27. This program was previously subject to Surface’s collaboration with Novartis. IL-27 is a novel target in immuno-oncology, believed to play a significant and broad role in tumor-related immunosuppression via the regulation of checkpoint protein expression.

  • GlobeNewswire3 months ago

    Publication in ImmunoHorizons Highlights the Role of IL-27 in Upregulation of Multiple Checkpoint Proteins

    - Expression of IL-27 shown to contribute to upregulation of PD-L1, LAG-3, CTLA-4, and TIGIT - Surface Oncology will submit an IND for SRF388, a first-in-class IL-27 antibody,.

  • ACCESSWIRE3 months ago

    Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause

    TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.

  • GlobeNewswire4 months ago

    Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board

    Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific advisory board (SAB). “Surface Oncology continues to grow and learn as a company and we look to align ourselves with world-class leaders in the fields of oncology and immunology. Steve is a clinical pioneer in the field of cancer immunotherapy.

  • GlobeNewswire4 months ago

    Surface Oncology Added to the NASDAQ Biotechnology Index

    CAMBRIDGE, Mass., Dec. 21, 2018 -- Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.

  • GlobeNewswire4 months ago

    Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021

    “A disciplined approach to both drug development and portfolio prioritization is central to our mission to develop truly innovative immunotherapies to help those affected by cancer,” said Jeff Goater, chief executive officer of Surface Oncology.

  • GlobeNewswire4 months ago

    Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations

    Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president, finance and business operations.  She is now responsible for the finance, information technology and facilities functions at Surface. Ms. Fees will also serve as the company’s principal financial and accounting officer, effective December 14, 2018.

  • GlobeNewswire5 months ago

    Surface Oncology Announces Upcoming Investor Presentations

    Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor conferences in the month of November. Members of the management team of Surface Oncology will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference, Tuesday, November 27th, 8:30 a.m. ET at the Lotte Palace Hotel, New York City. Additionally, members of management will participate in the Evercore ISI HealthCONx Conference, Wednesday, November 28, 2:20 p.m. ET at the Boston Harbor Hotel, Boston.

  • GlobeNewswire5 months ago

    Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2018

    CAMBRIDGE, Mass., Nov. 13, 2018 -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor.

  • Benzinga7 months ago

    Surface Oncology Offers 'Robust Pipeline,' Baird Says In Bullish Initiation

    In the next few years, Ulz said he anticipates "meaningful upside" stemming from early clinical data on antibodies that inhibit CD47, such as SRF231. The drug has broad utility and a differentiated safety profile, Ulz said. A Novartis AG (NYSE: NVS) partnership should target the adenosine pathway, leading to immunosuppression, Ulz said.

  • ACCESSWIRE10 months ago

    Kaskela Law LLC Announces Investigation of Surface Oncology, Inc. on Behalf of Stockholders

    RADNOR, PA / ACCESSWIRE / June 20, 2018 / Kaskela Law LLC is investigating Surface Oncology, Inc. ("Surface Oncology" or the "Company") (NASDAQ: SURF) on behalf of the Company's stockholders. ...

  • Stocks Keep Paring Losses, But Dow Jones Still Lags As This Chipmaker Tumbles
    Investor's Business Daily10 months ago

    Stocks Keep Paring Losses, But Dow Jones Still Lags As This Chipmaker Tumbles

    Stocks remained lower Monday afternoon, when the Dow Jones industrial average tumbled, but indexes in general continued to pare losses.